骨质疏松症药物治疗的必由之路：长程序贯治疗

被引：35

作者：

李梅 ^{[1
]}

章振林 ^{[2
]}

夏维波 ^{[1
]}

机构：

[1] 中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室

[2] 上海交通大学附属第六人民医院骨质疏松和骨病专科

来源：

中华骨质疏松和骨矿盐疾病杂志 | 2021年 / 14卷 / 05期

基金：

北京市自然科学基金; 国家重点研发计划;

关键词：

骨质疏松症; 骨吸收抑制剂; 骨形成促进剂; 序贯治疗;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

随着社会人口老龄化,我国骨质疏松症患病率急剧攀升。有效防控骨质疏松症,减少骨质疏松性骨折发生率,对于减轻疾病对国民健康和社会经济的危害具有重要意义。目前骨质疏松症治疗药物主要包括骨吸收抑制剂、骨形成促进剂和双重作用药物,上述药物长程序贯治疗能够持续增加骨密度、降低骨折风险,是骨质疏松症药物治疗的必然趋势,但基于骨折风险的科学序贯治疗方案仍需深入探索。

引用

页码：441 / 446

页数：6

共 27 条

[1]

Hu, Jing ;

Zheng, Wenbing ;

Zhao, Dichen ;

Sun, Lei ;

Zhou, Bingna ;

Liu, Jiayi ;

Wang, Ou ;

Jiang, Yan ;

Xia, Weibo ;

Xing, Xiaoping ;

Li, Mei .

ENDOCRINE, 2021, 74 (02) :270-280

[2]

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS..[J].Tsourdi Elena;Zillikens M Carola;Meier Christian;Body JeanJacques;Gonzalez Rodriguez Elena;Anastasilakis Athanasios D;Abrahamsen Bo;McCloskey Eugene;Hofbauer Lorenz C;Guañabens Nuria;ObermayerPietsch Barbara;Ralston Stuart H;Eastell Richard;Pepe Jessica;Palermo Andrea;Langdahl Bente.The Journal of clinical endocrinology and metabolism.2020,

[3]

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment [J].

Kondo, Hideomi ;

Okimoto, Nobukazu ;

Yoshioka, Toru ;

Akahoshi, Shojiro ;

Fuse, Yoshifumi ;

Ogawa, Takayuki ;

Okazaki, Yuichi ;

Katae, Yuji ;

Tsukamoto, Manabu ;

Yamanaka, Yoshiaki ;

Kawasaki, Makoto ;

Sakai, Akinori .

JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (06) :894-902

[4]

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab [J].

McClung, M. R. ;

Bolognese, M. A. ;

Brown, J. P. ;

Reginster, J-Y ;

Langdahl, B. L. ;

Maddox, J. ;

Shi, Y. ;

Rojeski, M. ;

Meisner, P. D. ;

Grauer, A. .

OSTEOPOROSIS INTERNATIONAL, 2020, 31 (11) :2231-2241

[5]

Determinants of imminent fracture risk in postmenopausal women with osteoporosis [J].

Barron, R. L. ;

Oster, G. ;

Grauer, A. ;

Crittenden, D. B. ;

Weycker, D. .

OSTEOPOROSIS INTERNATIONAL, 2020, 31 (11) :2103-2111

[6]

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis [J].

Leder, Benjamin Z. ;

Mitlak, Bruce ;

Hu, Ming-Yi ;

Hattersley, Gary ;

Bockman, Richard S. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03) :938-943

[7]

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update [J].

Shoback, Dolores ;

Rosen, Clifford J. ;

Black, Dennis M. ;

Cheung, Angela M. ;

Murad, M. Hassan ;

Eastell, Richard .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03) :587-594

[8]

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures [J].

Kanis, J. A. ;

Harvey, N. C. ;

McCloskey, E. ;

Bruyere, O. ;

Veronese, N. ;

Lorentzon, M. ;

Cooper, C. ;

Rizzoli, R. ;

Adib, G. ;

Al-Daghri, N. ;

Campusano, C. ;

Chandran, M. ;

Dawson-Hughes, B. ;

Javaid, K. ;

Jiwa, F. ;

Johansson, H. ;

Lee, J. K. ;

Liu, E. ;

Messina, D. ;

Mkinsi, O. ;

Pinto, D. ;

Prieto-Alhambra, D. ;

Saag, K. ;

Xia, W. ;

Zakraoui, L. ;

Reginster, J. -Y. .

OSTEOPOROSIS INTERNATIONAL, 2020, 31 (01) :1-12

[9]

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE..[J].Camacho Pauline M;Petak Steven M;Binkley Neil;Diab Dima L;Eldeiry Leslie S;Farooki Azeez;Harris Steven T;Hurley Daniel L;Kelly Jennifer;Lewiecki E Michael;Pessah-Pollack Rachel;McClung Michael;Wimalawansa Sunil J;Watts Nelson B.Endocrine practice : official journal of the American College of Endocrinology

[10]

Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.[J].Bente Langdahl.Bone.2020, prepublish

← 1 2 3 →